Disability progression in aggressive multiple sclerosis

Suresh Menon, Feng Zhu, Afsaneh Shirani, Joel Oger, Mark S. Freedman, Helen Tremlett

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: To examine disease progression in 'aggressive' multiple sclerosis (MS), British Columbia, Canada (1980-2009). Methods: Aggressive (or 'malignant') MS was defined as Expanded Disability Status Scale (EDSS) ≥3/46 within 5 years from onset. The first EDSS ≥3/46 was termed 'baseline'. Within 2, 3 and 5 years post-baseline, patients were categorized as follows: 'worsened' or 'improved', relative to baseline EDSS (the remainder exhibited no change or had no new scores). The associations between patient characteristics (sex, relapsing onset/primary progressive, onset age, onset symptoms, disease duration, cumulative prior relapses and baseline EDSS) and worsening in disability were examined longitudinally using logistic regression. Results: Of the 225/4341 (5.2%) aggressive/malignant MS patients, 134 (59.6%) were female, 167 (74.2%) were relapsing onset, 94 (41.8%) had received disease-modifying drugs at some point and the mean follow-up was 8.7 years. The proportion of patients who 'worsened' increased from 40.4% to 57.8%, while those who 'improved' varied little (range, 8.9%-10.2%). The odds of worsening increased with disease duration (adjusted odds ratio (AOR) = 1.36; 95% confidence interval (CI) = 1.22-1.52) and the presence of primary progressive (vs relapsing-onset) MS (AOR = 1.85; 95% CI = 1.01-3.38). Conclusion: Apart from disease duration and a primary progressive course, no clinically useful associations of subsequent disease worsening in patients with aggressive/malignant MS were identified.

Original languageEnglish (US)
Pages (from-to)456-463
Number of pages8
JournalMultiple Sclerosis
Volume23
Issue number3
DOIs
StatePublished - Mar 1 2017

Fingerprint

Multiple Sclerosis
Odds Ratio
Confidence Intervals
British Columbia
Age of Onset
Sex Characteristics
Canada
Disease Progression
Logistic Models
Recurrence
Pharmaceutical Preparations

Keywords

  • Multiple sclerosis
  • epidemiology
  • neuroepidemiology

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Menon, S., Zhu, F., Shirani, A., Oger, J., Freedman, M. S., & Tremlett, H. (2017). Disability progression in aggressive multiple sclerosis. Multiple Sclerosis, 23(3), 456-463. https://doi.org/10.1177/1352458516653273

Disability progression in aggressive multiple sclerosis. / Menon, Suresh; Zhu, Feng; Shirani, Afsaneh; Oger, Joel; Freedman, Mark S.; Tremlett, Helen.

In: Multiple Sclerosis, Vol. 23, No. 3, 01.03.2017, p. 456-463.

Research output: Contribution to journalArticle

Menon, S, Zhu, F, Shirani, A, Oger, J, Freedman, MS & Tremlett, H 2017, 'Disability progression in aggressive multiple sclerosis', Multiple Sclerosis, vol. 23, no. 3, pp. 456-463. https://doi.org/10.1177/1352458516653273
Menon, Suresh ; Zhu, Feng ; Shirani, Afsaneh ; Oger, Joel ; Freedman, Mark S. ; Tremlett, Helen. / Disability progression in aggressive multiple sclerosis. In: Multiple Sclerosis. 2017 ; Vol. 23, No. 3. pp. 456-463.
@article{2b9ee114d454443cb205b87e648e0879,
title = "Disability progression in aggressive multiple sclerosis",
abstract = "Objective: To examine disease progression in 'aggressive' multiple sclerosis (MS), British Columbia, Canada (1980-2009). Methods: Aggressive (or 'malignant') MS was defined as Expanded Disability Status Scale (EDSS) ≥3/46 within 5 years from onset. The first EDSS ≥3/46 was termed 'baseline'. Within 2, 3 and 5 years post-baseline, patients were categorized as follows: 'worsened' or 'improved', relative to baseline EDSS (the remainder exhibited no change or had no new scores). The associations between patient characteristics (sex, relapsing onset/primary progressive, onset age, onset symptoms, disease duration, cumulative prior relapses and baseline EDSS) and worsening in disability were examined longitudinally using logistic regression. Results: Of the 225/4341 (5.2{\%}) aggressive/malignant MS patients, 134 (59.6{\%}) were female, 167 (74.2{\%}) were relapsing onset, 94 (41.8{\%}) had received disease-modifying drugs at some point and the mean follow-up was 8.7 years. The proportion of patients who 'worsened' increased from 40.4{\%} to 57.8{\%}, while those who 'improved' varied little (range, 8.9{\%}-10.2{\%}). The odds of worsening increased with disease duration (adjusted odds ratio (AOR) = 1.36; 95{\%} confidence interval (CI) = 1.22-1.52) and the presence of primary progressive (vs relapsing-onset) MS (AOR = 1.85; 95{\%} CI = 1.01-3.38). Conclusion: Apart from disease duration and a primary progressive course, no clinically useful associations of subsequent disease worsening in patients with aggressive/malignant MS were identified.",
keywords = "Multiple sclerosis, epidemiology, neuroepidemiology",
author = "Suresh Menon and Feng Zhu and Afsaneh Shirani and Joel Oger and Freedman, {Mark S.} and Helen Tremlett",
year = "2017",
month = "3",
day = "1",
doi = "10.1177/1352458516653273",
language = "English (US)",
volume = "23",
pages = "456--463",
journal = "Multiple Sclerosis Journal",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "3",

}

TY - JOUR

T1 - Disability progression in aggressive multiple sclerosis

AU - Menon, Suresh

AU - Zhu, Feng

AU - Shirani, Afsaneh

AU - Oger, Joel

AU - Freedman, Mark S.

AU - Tremlett, Helen

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Objective: To examine disease progression in 'aggressive' multiple sclerosis (MS), British Columbia, Canada (1980-2009). Methods: Aggressive (or 'malignant') MS was defined as Expanded Disability Status Scale (EDSS) ≥3/46 within 5 years from onset. The first EDSS ≥3/46 was termed 'baseline'. Within 2, 3 and 5 years post-baseline, patients were categorized as follows: 'worsened' or 'improved', relative to baseline EDSS (the remainder exhibited no change or had no new scores). The associations between patient characteristics (sex, relapsing onset/primary progressive, onset age, onset symptoms, disease duration, cumulative prior relapses and baseline EDSS) and worsening in disability were examined longitudinally using logistic regression. Results: Of the 225/4341 (5.2%) aggressive/malignant MS patients, 134 (59.6%) were female, 167 (74.2%) were relapsing onset, 94 (41.8%) had received disease-modifying drugs at some point and the mean follow-up was 8.7 years. The proportion of patients who 'worsened' increased from 40.4% to 57.8%, while those who 'improved' varied little (range, 8.9%-10.2%). The odds of worsening increased with disease duration (adjusted odds ratio (AOR) = 1.36; 95% confidence interval (CI) = 1.22-1.52) and the presence of primary progressive (vs relapsing-onset) MS (AOR = 1.85; 95% CI = 1.01-3.38). Conclusion: Apart from disease duration and a primary progressive course, no clinically useful associations of subsequent disease worsening in patients with aggressive/malignant MS were identified.

AB - Objective: To examine disease progression in 'aggressive' multiple sclerosis (MS), British Columbia, Canada (1980-2009). Methods: Aggressive (or 'malignant') MS was defined as Expanded Disability Status Scale (EDSS) ≥3/46 within 5 years from onset. The first EDSS ≥3/46 was termed 'baseline'. Within 2, 3 and 5 years post-baseline, patients were categorized as follows: 'worsened' or 'improved', relative to baseline EDSS (the remainder exhibited no change or had no new scores). The associations between patient characteristics (sex, relapsing onset/primary progressive, onset age, onset symptoms, disease duration, cumulative prior relapses and baseline EDSS) and worsening in disability were examined longitudinally using logistic regression. Results: Of the 225/4341 (5.2%) aggressive/malignant MS patients, 134 (59.6%) were female, 167 (74.2%) were relapsing onset, 94 (41.8%) had received disease-modifying drugs at some point and the mean follow-up was 8.7 years. The proportion of patients who 'worsened' increased from 40.4% to 57.8%, while those who 'improved' varied little (range, 8.9%-10.2%). The odds of worsening increased with disease duration (adjusted odds ratio (AOR) = 1.36; 95% confidence interval (CI) = 1.22-1.52) and the presence of primary progressive (vs relapsing-onset) MS (AOR = 1.85; 95% CI = 1.01-3.38). Conclusion: Apart from disease duration and a primary progressive course, no clinically useful associations of subsequent disease worsening in patients with aggressive/malignant MS were identified.

KW - Multiple sclerosis

KW - epidemiology

KW - neuroepidemiology

UR - http://www.scopus.com/inward/record.url?scp=85014806629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014806629&partnerID=8YFLogxK

U2 - 10.1177/1352458516653273

DO - 10.1177/1352458516653273

M3 - Article

C2 - 27325603

AN - SCOPUS:85014806629

VL - 23

SP - 456

EP - 463

JO - Multiple Sclerosis Journal

JF - Multiple Sclerosis Journal

SN - 1352-4585

IS - 3

ER -